Loading organizations...
§ Private Profile · London, United Kingdom
Male fertility at-home sperm testing platform for men, offering personalized advice. Supports clinics, corporates, and healthcare organizations.
Based in London, United Kingdom, ExSeed Health develops a clinically robust smartphone platform for at-home sperm quality testing that accurately analyzes male fertility and provides personalized health advice. The reproductive health technology enterprise sells diagnostic kits directly to consumers and supplies international clinics, corporate partners, and global healthcare organizations, facilitating over 65,000 individual tests. By enabling private testing and treatment, the business aims to shift the traditional medical focus away from women-centric infertility solutions toward earlier male detection. The startup has garnered significant industry recognition, including a top ranking from Forbes, a placement on the worldwide Disrupt 100 list, and a feature on BBC World News. Founded in 2017 by Morten G Ulsted and Doctor Emil Andersen, the company partners with Trifork eHealth to expand its digital infrastructure across European markets like Denmark and Norway.
ExSeed Health has raised $4.4M across 2 funding rounds.
ExSeed Health has raised $4.4M in total across 2 funding rounds.
ExSeed Health has raised $4.4M across 2 funding rounds. Most recently, it raised $3.4M Seed Extension in February 2022.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Feb 15, 2022 | $3.4M Seed Plus | Ozgur Tuncer | Dominic Perks, R42 Group, Trifork Labs | Announced |
| Feb 1, 2020 | $1M Seed | — | Friále, Hambro Perks, Y Combinator, Louis Beryl | Announced |
ExSeed Health is a health technology company specializing in male reproductive health, offering an at-home sperm analysis device powered by AI to assess sperm concentration and motility, alongside personalized lifestyle programs for fertility improvement[1][2][3]. It serves individuals and couples seeking convenient, private fertility insights without clinic visits, addressing male infertility—a factor in about half of infertility cases—through accessible testing and support[1][2]. Founded in 2017 with a Seed VC funding round, the company has demonstrated early growth in the burgeoning at-home fertility testing market, competing with players like Medical Electronic Systems (YO Home Sperm Test) and Mojo[1].
ExSeed Health emerged in 2017 from Denmark, initially developing medical devices and mobile apps focused on male infertility treatment[2]. The core idea—a state-of-the-art home device where users insert a semen sample into a glass slide and place a smartphone on top for AI-driven analysis of sperm quality—arose to make fertility testing private and accessible[1][2][3]. Founders' backgrounds are not detailed in available sources, but early traction centered on this innovative hardware-software combo, leading to headquarters relocation to London, England, at 6 Hooker's Road, and a Seed VC funding round[1][2]. This pivot from Denmark to the UK reflects strategic scaling in Europe's health tech ecosystem[1][2].
ExSeed Health stands out in the male fertility space through these key features:
ExSeed Health rides the wave of consumerized health tech, particularly at-home diagnostics amplified by AI and smartphones, amid rising infertility rates (affecting 1 in 6 couples globally) and demand for male-focused solutions long overshadowed by female fertility tools[1]. Timing aligns with post-pandemic shifts to telehealth and direct-to-consumer biotech, fueled by market forces like smartphone ubiquity and AI advancements in image analysis for biology[2][3]. By democratizing male fertility data, it influences the ecosystem—empowering proactive health decisions, reducing clinic overload, and spurring competition that elevates standards in reproductive health tech[1].
ExSeed Health is poised for expansion through product iterations (e.g., enhanced AI, telemedicine integrations) and potential Series A funding, capitalizing on the $5B+ fertility market's growth at 8-10% CAGR[1]. Trends like personalized medicine, wearable health data synergy, and global awareness campaigns will shape its path, potentially evolving it into a full-stack male reproductive platform. As at-home testing normalizes, ExSeed could redefine fertility journeys, turning early detection into family-building empowerment—much like its founding device brought clinic-grade insights home.
ExSeed Health has raised $4.4M in total across 2 funding rounds.
ExSeed Health's investors include Ozgur Tuncer, Dominic Perks, R42 Group, Trifork Labs, Friále, Hambro Perks, Y Combinator, Louis Beryl.